Stefano Ricagno, PhD, University of Milan, Milan, Italy, shares some insights into AL amyloidosis with cardiac involvement, emphasizing the need to further research and better understand the molecular underpinnings of cardiotoxicity in this disease. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

Binoy Yohannan, MD, Mayo Clinic, Rochester, MN, shares insights into a real-world study exploring the outcomes of patients with light chain (AL) amyloidosis treated with a bortezomib-based regimen versus daratumumab-based frontline therapy. Patients in the daratumumab arm demonstrated an improvement in hematologic response and organ response, which translated to a superior event-free and overall survival (EFS; OS). These findings further support the use of daratumumab-based frontline therapy in AL amyloidosis. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Phillip Scheinberg, MD, PhD, Beneficencia Portuguesa de Sao Paulo, São Paulo, Brazil, discusses the use of transplantation in 30 patients with light chain (AL) amyloidosis at his center in São Paulo, Brazil. He highlights low mortality rates in this historically high-risk group, showcasing the efficacy of this treatment approach even in a resource-limited setting. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Current medical education on amyloid diseases is 25 years old and materially outdated, punctuated by rapid advancement in the last five years. Hear from renowned Dr. Jeff Kelly from Scripps Research, developer of ATTR drug Tafamidis, about the current biology and how amyloid diseases such as the Systemic Amyloidoses (ATTR and AL), Parkinson’s and Alzheimer's are today believed to be more similar than different.

Emily Brown, MGC, CGC
Certified Genetic Counselor
Center for Inherited Heart Disease
Johns Hopkins University, Baltimore, MD

Presented at the 2023 Amyloidosis Support Groups ATTR/Hereditary Meeting, Saturday, October 28, 2023

This video is about imaging cardiac amyloidosis, principally with bone scintigraphy.

Join our expert faculty to hear about newly-approved drug therapy for patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

- - - - -
Faculty: Michelle M. Kittleson, MD, PhD
Faculty: Ahmad Masri, MD, MS
- - - - -

Earn free 0.50 AMA PRA Category 1 Credit™. Access for credit will be shared at the end of this live event.

Click the link to view the Accreditation and Disclosure details before participating: Medscape.org/viewarticle/1001970.

Supported by an independent educational grant from BridgeBio.